Krankheitsbilder im Alter: Polymyalgia rheumatica, Riesenzellarteriitis, Schnitzler-Syndrom und VEXAS-Syndrom

Zusammenfassung

Die Behandlung von älteren Patient:innen bedarf besonderer Aufmerksamkeit und spezieller Fachkenntnisse. Altersbedingte Veränderungen des Immunsystems, multiple Komorbiditäten und eine altersabhängige Pharmakokinetik und -dynamik erfordern eine individuelle und sorgfältige Herangehensweise. Ziel dieses Artikels ist es, aktuelle Erkenntnisse und praxisrelevante Ansätze zur Diagnostik und Therapie ausgewählter rheumatologischer Erkrankungen im höheren Lebensalter, wie Polymyalgia rheumatica (PMR), Riesenzellarteriitis (RZA), Schnitzler-Syndrom und VEXAS-Syndrom zu präsentieren.

Abstract

The treatment of elderly patients requires special attention and expertise. Age-related changes of the immune system, multiple comorbidities and age-dependent pharmacokinetics and pharmacodynamics call for an individualised and careful approach. This article aims to present current insights and practical approaches to the diagnosis and treatment of selected rheumatological diseases in elderly patients, e. g. polymyalgia rheumatica (PMR), giant cell arteritis (GCA), Schnitzler syndrome, and VEXAS syndrome.

Schlüsselwörter

Polymyalgia rheumatica - Riesenzellarteriitis - Schnitzler-Syndrom - VEXAS-Syndrom

Keywords

polymyalgia rheumatica - giant cell arteritis - Schnitzler syndrome - VEXAS syndrome

Publication History

Article published online:
26 September 2024

• Literatur

• 1 Nielsen AW, Frolund LL, Vaben C. et al. Concurrent baseline diagnosis of giant cell arteritis and polymyalgia rheumatica – A systematic review and meta-analysis. Semin Arthritis Rheum 2022; 56: 152069
• 2 Salvarani C, Cantini F, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. Lancet 2008; 372: 234-245
• 3 Dejaco C, Duftner C, Buttgereit F. et al. The spectrum of giant cell arteritis and polymyalgia rheumatica: revisiting the concept of the disease. Rheumatology (Oxford) 2017; 56: 506-515
• 4 Gonzalez-Gay MA, Vazquez-Rodriguez TR, Lopez-Diaz MJ. et al. Epidemiology of giant cell arteritis and polymyalgia rheumatica. Arthritis Rheum 2009; 61: 1454-1461
• 5 De Miguel E, Macchioni P, Conticini E. et al. Prevalence and characteristics of subclinical giant cell arteritis in polymyalgia rheumatica. Rheumatology (Oxford) 2024; 63: 158-164
• 6 De Miguel E, Karalilova R, Macchioni P. et al. Subclinical giant cell arteritis increases the risk of relapse in polymyalgia rheumatica. Ann Rheum Dis 2024; 83: 335-341
• 7 Diamantopoulos AP, Haugeberg G, Lindland A. et al. The fast-track ultrasound clinic for early diagnosis of giant cell arteritis significantly reduces permanent visual impairment: towards a more effective strategy to improve clinical outcome in giant cell arteritis?. Rheumatology (Oxford) 2016; 55: 66-70
• 8 Monti S, Bartoletti A, Bellis E. et al. Fast-Track Ultrasound Clinic for the Diagnosis of Giant Cell Arteritis Changes the Prognosis of the Disease but Not the Risk of Future Relapse. Front Med (Lausanne) 2020; 7: 589794
• 9 Patil P, Williams M, Maw WW. et al. Fast track pathway reduces sight loss in giant cell arteritis: results of a longitudinal observational cohort study. Clin Exp Rheumatol 2015; 33: S-103-106
• 10 Schmidt WA, Czihal M, Gernert M. et al Recommendations for defining giant cell arteritis fast-track clinics. Z Rheumatol 2024; 10.1007/s00393-024-01519-6
• 11 Green DJ, Muller S, Mallen CD. et al. Fatigue as a precursor to polymyalgia rheumatica: an explorative retrospective cohort study. Scand J Rheumatol 2015; 44: 219-223
• 12 Dasgupta B, Cimmino MA, Maradit-Kremers H. et al. 2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Ann Rheum Dis 2012; 71: 484-492
• 13 Ponte C, Grayson PC, Robson JC. et al. 2022 American College of Rheumatology/EULAR classification criteria for giant cell arteritis. Ann Rheum Dis 2022; 81: 1647-1653
• 14 Dejaco C, Kerschbaumer A, Aletaha D. et al. Treat-to-target recommendations in giant cell arteritis and polymyalgia rheumatica. Ann Rheum Dis 2024; 83: 48-57
• 15 Muratore F, Pipitone N, Hunder GG. et al. Discontinuation of therapies in polymyalgia rheumatica and giant cell arteritis. Clin Exp Rheumatol 2013; 31: S86-92
• 16 Ayoub WT, Franklin CM, Torretti D. Polymyalgia rheumatica. Duration of therapy and long-term outcome. Am J Med 1985; 79: 309-315
• 17 Buttgereit F, Dgrh Brabant T. et al. [S3 guidelines on treatment of polymyalgia rheumatica : Evidence-based guidelines of the German Society of Rheumatology (DGRh), the Austrian Society of Rheumatology and Rehabilitation (OGR) and the Swiss Society of Rheumatology (SGT) and participating medical scientific specialist societies and other organizations]. Z Rheumatol 2018; 77: 429-441
• 18 Floris A, Piga M, Chessa E. et al. Long-term glucocorticoid treatment and high relapse rate remain unresolved issues in the real-life management of polymyalgia rheumatica: a systematic literature review and meta-analysis. Clin Rheumatol 2022; 41: 19-31
• 19 Marsman D, Bolhuis T, Broeder ND. et al. Effect of add-on methotrexate in polymyalgia rheumatica patients flaring on glucocorticoids tapering: a retrospective study. Rheumatol Int 2021; 41: 611-616
• 20 Devauchelle-Pensec V, Carvajal-Alegria G, Dernis E. et al. Effect of Tocilizumab on Disease Activity in Patients With Active Polymyalgia Rheumatica Receiving Glucocorticoid Therapy: A Randomized Clinical Trial. JAMA 2022; 328: 1053-1062
• 21 Schmidt WA. [Sarilumab for polymyalgia rheumatica]. Z Rheumatol 2024; 83: 151-152
• 22 Schirmer JH, Aries PM, Balzer K. et al. [S2k guidelines: management of large-vessel vasculitis]. Z Rheumatol 2020; 79: 67-95
• 23 Venhoff N, Schmidt WA, Bergner R. et al. Safety and efficacy of secukinumab in patients with giant cell arteritis (TitAIN): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Rheumatol 2023; 5: e341-e350
• 24 Blockmans SKP D., Setty A., Schmidt W., Rubbert-Roth A., Hauge E.M., Keen H., Ishii T., Khalidi N., Liu M., Zhao W., Lagunes I., Romero A., Wung P.K. P. A. Merkel. LBA0001 EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH GIANT CELL ARTERITIS (SELECT-GCA): A DOUBLE-BLIND, RANDOMIZED CONTROLLED PHASE 3 TRIAL. Annals of the Rheumatic Diseases. 2024
• 25 Abukanna AM, Alanazi YF, Alanazi FWS. et al. Updates on the Prognosis of Giant Cell Arteritis: A Systematic Review. Cureus 2023; 15: e50299
• 26 de Koning HD, Bodar EJ, van der Meer JW. et al. Schnitzler syndrome: beyond the case reports: review and follow-up of 94 patients with an emphasis on prognosis and treatment. Semin Arthritis Rheum 2007; 37: 137-148
• 27 Simon A, Asli B, Braun-Falco M. et al. Schnitzler's syndrome: diagnosis, treatment, and follow-up. Allergy 2013; 68: 562-568
• 28 Bonnekoh H, Scheffel J, Maurer M. et al. Use of skin biomarker profiles to distinguish Schnitzler syndrome from chronic spontaneous urticaria: results of a pilot study. Br J Dermatol 2018; 178: 561-562
• 29 Krause K, Bonnekoh H, Ellrich A. et al. Long-term efficacy of canakinumab in the treatment of Schnitzler syndrome. J Allergy Clin Immunol 2020; 145: 1681-1686 e1685
• 30 Krause K, Weller K, Stefaniak R. et al. Efficacy and safety of the interleukin-1 antagonist rilonacept in Schnitzler syndrome: an open-label study. Allergy 2012; 67: 943-950
• 31 Bonnekoh H, Frischbutter S, Roll S. et al. Tocilizumab treatment in patients with Schnitzler syndrome: An open-label study. J Allergy Clin Immunol Pract 2021; 9: 2486-2489 e2484
• 32 Beck DB, Bodian DL, Shah V. et al. Estimated Prevalence and Clinical Manifestations of UBA1 Variants Associated With VEXAS Syndrome in a Clinical Population. JAMA 2023; 329: 318-324
• 33 Beck DB, Ferrada MA, Sikora KA. et al. Somatic Mutations in UBA1 and Severe Adult-Onset Autoinflammatory Disease. N Engl J Med 2020; 383: 2628-2638
• 34 Georgin-Lavialle S, Terrier B, Guedon AF. et al. Further characterization of clinical and laboratory features in VEXAS syndrome: large-scale analysis of a multicentre case series of 116 French patients. Br J Dermatol 2022; 186: 564-574
• 35 Koster MJ, Kourelis T, Reichard KK. et al. Clinical Heterogeneity of the VEXAS Syndrome: A Case Series. Mayo Clin Proc 2021; 96: 2653-2659
• 36 Kreutzinger V, Pankow A, Boyadzhieva Z. et al. VEXAS and Myelodysplastic Syndrome: An Interdisciplinary Challenge. J Clin Med 2024; 13
• 37 Ferrada MA, Sikora KA, Luo Y. et al. Somatic Mutations in UBA1 Define a Distinct Subset of Relapsing Polychondritis Patients With VEXAS. Arthritis Rheumatol 2021; 73: 1886-1895
• 38 Tsuchida N, Kunishita Y, Uchiyama Y. et al. Pathogenic UBA1 variants associated with VEXAS syndrome in Japanese patients with relapsing polychondritis. Ann Rheum Dis 2021; 80: 1057-1061
• 39 Phan L, Hammond D, Wilson NR. et al VEXAS syndrome (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic): clinical review in a rapidly emerging field. Leuk Lymphoma 2024; 1-13. doi:10.1080/10428194.2024.2349950
• 40 Kusne Y, Ghorbanzadeh A, Dulau-Florea A. et al. Venous and arterial thrombosis in patients with VEXAS syndrome. Blood 2024; 143: 2190-2200
• 41 Ruffer N, Krusche M. VEXAS syndrome: a diagnostic puzzle. RMD Open 2023; 9
• 42 Bruno A, Gurnari C, Alexander T. et al. Autoimmune manifestations in VEXAS: Opportunities for integration and pitfalls to interpretation. J Allergy Clin Immunol 2023; 151: 1204-1214
• 43 Gurnari C, Pagliuca S, Durkin L. et al. Vacuolization of hematopoietic precursors: an enigma with multiple etiologies. Blood 2021; 137: 3685-3689
• 44 Hadjadj J, Nguyen Y, Mouloudj D. et al Efficacy and safety of targeted therapies in VEXAS syndrome: retrospective study from the FRENVEX. Ann Rheum Dis 2024; doi:10.1136/ard-2024-225640
• 45 Mekinian A, Zhao LP, Chevret S. et al. A Phase II prospective trial of azacitidine in steroid-dependent or refractory systemic autoimmune/inflammatory disorders and VEXAS syndrome associated with MDS and CMML. Leukemia 2022; 36: 2739-2742
• 46 Comont T, Heiblig M, Riviere E. et al. Azacitidine for patients with Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic syndrome (VEXAS) and myelodysplastic syndrome: data from the French VEXAS registry. Br J Haematol 2022; 196: 969-974
• 47 Gurnari C, Koster L, Baaij L. et al. Allogeneic hematopoietic cell transplantation for VEXAS syndrome: results of a multicenter study of the EBMT. Blood Adv 2024; 8: 1444-1448
• 48 Mangaonkar AA, Langer KJ, Lasho TL. et al. Reduced intensity conditioning allogeneic hematopoietic stem cell transplantation in VEXAS syndrome: Data from a prospective series of patients. Am J Hematol 2023; 98: E28-E31